Christopher Gibson, Chief Executive Officer at RECURSION PHARMACEUTICALS, INC. (RXRX), sold 40,000 shares at $6.37 ($259K) on 2025-03-06, disclosed to the SEC on 2025-03-07.
Scheduled sale ($259k) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $6.58 | 20,000 | $132K | 50.8% |
| 2 | $6.37 | 20,000 | $127K | 49.2% |
| Total | $6.47 avg | 40,000 | $259K | 100% |
| Filing → |
| RXRX | SELL | 2026-05-08 | $135K | — | Filing → |
| RXRX | SELL | 2026-04-24 | $144K | — | Filing → |
| RXRX | SELL | 2026-04-08 | $124K | — | Filing → |